Clinical trial
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive…
NCT00220363 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00220363 |
|---|---|
| Title | A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome |
| Official title | A Phase 3, Parallel Group, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Overactive Bladder Syndrome |
| Intervention type | Drug |
| Interventions | SPM 907 |
| Start date | Jan 1, 2004 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | May 5, 2008 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: